

RECEIVED  
CENTRAL FAX CENTER

SEP 30 2004

PATENT  
Docket No. 180.0003 0103IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Hanson et al.	)	Group Art Unit:	1634
	)		
Serial No.: 09/814,252	)	Examiner:	Frank Lu
Confirmation No.: 6198	)		
	)		
Filed: 21 March 2001	)		
	)		
For: PRIMERS FOR USE IN DETECTING BETA-LACTAMASES	)		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed are copies of documents which Applicants bring to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Per M.P.E.P. § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested. Pursuant to the provisions of MPEP §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Supplemental Information Disclosure Statement is submitted after receipt of an Office Action in the above-identified patent application, Applicants have included the fee of \$180 under 37 CFR §§1.97(c) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

## Supplemental Information Disclosure Statement

Page 2 of 2

Applicant(s): Hanson et al.

Serial No.: 09/814,252

Confirmation No.: 6198

Filed: 21 March 2001

For: PRIMERS FOR USE IN DETECTING BETA-LACTAMASES

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

## CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 30<sup>th</sup> day of September, 2004, at 4:40 PM (Central Time).

*Kenneth L. Franklin*  
Kenneth L. Franklin

Sept 30, 2004  
Date

Respectfully submitted for

Hanson et al.

By  
Mueting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Telephone (612)305-1220  
Facsimile (612)305-1228  
Customer Number 26813

By: *Ann M. Mueting*  
Ann M. Mueting  
Reg. No. 33,977  
Direct Dial (612)305-1217

SEP 30 2004

OMB No. 0651-0011

Page 1 of 1

<b>INFORMATION DISCLOSURE STATEMENT</b>	Atty. Docket No.: 180.0003 0103	Serial No.: 09/814,252
	Applicant(s): Hanson et al.	Confirmation No.: 6198
	Application Filing Date: 21 March 2001	Group: 1634
	Information Disclosure Statement mailed:	

**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	NONE					

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	NONE						

**OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)**

Examiner Initial	Document Description
	Alksne et al., "Expression of the AsbA1, OXA-12, and AsbM1 $\beta$ -Lactamases in <i>Aeromonas jandaei</i> AER 14 IS Coordinated by a Two-Component Regulon," <i>Journal of Bacteriology</i> , 179(6):2006-2013 (1997).
	Daniel et al., "OXA-15, an Extended-Spectrum Variant of OXA-2 $\beta$ -Lactamase, Isolated from a <i>Pseudomonas aeruginosa</i> Strain," <i>Antimicrobial Agents and Chemotherapy</i> , 41(4):785-790 (1997).
	Rasmussen et al., "Cloning and Expression of a Cloxacillin-Hydrolyzing Enzyme and a Cephalosporinase from <i>Aeromonas sobria</i> AER 14M in <i>Escherichia coli</i> : Requirement for an <i>E. coli</i> Chromosomal Mutation for Efficient Expression of the Class D Enzyme," <i>Antimicrobial Agents and Chemotherapy</i> , 38(9):2078-2085 (1994).
	Scoulica et al., "Molecular Characterization of the OXA-7 $\beta$ -Lactamase Gene," <i>Antimicrobial Agents and Chemotherapy</i> , 39(6):1379-1382 (1995).
	Tolmasky et al., "Genetic Organization Antibiotic Resistant Genes ( <i>aac(6')</i> -Ib, <i>aadA</i> , and OXA-9) in the Multiresistance Transposon <i>Tn1331</i> ," <i>Plasmid</i> , 29:31-40 (1993).

<b>EXAMINER</b>	<b>Date Considered</b>
<small>*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	